Next generation diagnostic tool for identification of rheumatoid arthritis patients to improve treatment
|Coordinator||Vacara AB - Vacara AB, STOCKHOLM|
|Funding from Vinnova||SEK 1 000 000|
|Project duration||June 2017 - December 2018|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
Purpose and goal
Occurrence of autoantibodies in sera is associated with the development of rheumatoid arthritis (RA). However, the prognostic value of the current autoantibody tests used in clinic is limited. We have generated a first prototype of the Joint-ID Test, a Luminex-based multiplex assay for qualitative detection of autoantibodies requiring only one microliter of human serum. In order to reach the TRL5, the kit has been validated and certified by notified body at Research Institute of Sweden (RISE).
Expected results and effects
The Joint-ID Test has been clinical validated by using large human cohorts of RA patients (n=1120) and an independent cohort of healthy controls (n=398). We identified 17 peptides with a potential prognostic value in newly diagnosed RA patients, which is limited with the established and commercially available tests. These results imply that patients positive for these peptides are not responding well to standard treatment and may benefit from personalized treatment strategies. We have also identified 6 peptides with a potential diagnostic value.
Planned approach and implementation
Vacara AB has together with the other partners (Medical Inflammation Research at Karolinska Institutet, RISE and Sahlgrenska Universitetsjukhuset in Gothenburg) developed a second generation of the Joint-ID Test. A productive collaboration with Institute Pasteur of Shanghai and Shanghai Guanghua Integrative Medicine Hospital has been established to validate the Joint-ID kit in large human cohorts of pre-RA and RA patients in China. The large number of patients and heterogeneity in treatment practices will be of particular interest to predict treatment outcome.